FY2024 Earnings Estimate for Amarin Issued By Zacks Research

Amarin Co. plc (NASDAQ:AMRN) – Stock analysts at Zacks Research reduced their FY2024 EPS estimates for shares of Amarin in a research note issued to investors on Wednesday, January 8th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of ($0.18) per share for the year, down from their previous forecast of ($0.17). The consensus estimate for Amarin’s current full-year earnings is ($0.14) per share. Zacks Research also issued estimates for Amarin’s Q4 2024 earnings at ($0.10) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.30) EPS.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $42.30 million for the quarter, compared to analyst estimates of $43.82 million. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. During the same quarter in the previous year, the firm posted ($0.05) earnings per share.

Separately, StockNews.com began coverage on Amarin in a research note on Sunday, January 5th. They set a “sell” rating on the stock.

Amarin Price Performance

AMRN stock opened at $0.55 on Monday. Amarin has a 1 year low of $0.43 and a 1 year high of $1.37. The firm has a market capitalization of $226.61 million, a PE ratio of -6.13 and a beta of 1.82. The business has a 50 day simple moving average of $0.51 and a 200-day simple moving average of $0.60.

Hedge Funds Weigh In On Amarin

Institutional investors have recently bought and sold shares of the company. Algert Global LLC acquired a new stake in shares of Amarin during the 2nd quarter worth approximately $34,000. China Universal Asset Management Co. Ltd. increased its stake in Amarin by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 29,992 shares during the last quarter. Kornitzer Capital Management Inc. KS raised its position in Amarin by 80.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 42,700 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Amarin by 8.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock valued at $816,000 after purchasing an additional 104,939 shares during the last quarter. 22.25% of the stock is owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.